ROUNDUP: Federal government proposes Astrazeneca approval – vaccinations planned from twelve | message
Shares in this article
BERLIN (dpa-AFX) – According to the will of Health Minister Jens Spahn (CDU), those who want to be vaccinated should be able to be vaccinated against Corona in future regardless of the applicable priority list – if they choose AstraZeneca. Spahn made a corresponding move on Thursday during the deliberations of the specialist ministers
– Minister of the Federation and the States. That could help more people sooner
benefit from complete vaccination protection. 7.1 million or 8.6 percent of German citizens are currently fully vaccinated. Almost every third person has had at least one injection: 30.6 percent. In summer, all 12 to 15 year olds should also receive a vaccination offer. The vaccine is expected to be approved by Biontech (BioNTech (ADRs)) / Pfizer in June for ages 12 and over.
ASTRAZENECA FOR EVERYONE:
Nationwide, vaccination with the Astrazeneca vaccine will no longer be prioritized in future. This is what a draft resolution submitted by Spahn to the German Press Agency provides for the consultations with his country colleagues: “In medical practices, vaccinations with this vaccine can only be given to those willing to vaccinate (…) at the discretion of the doctor.” The federal government relies on a passage in the Vaccination Ordinance. According to this, the order can be deviated from, for example according to age, previous illnesses and occupational group, if this is necessary for efficient organization or the timely use of existing vaccines. Spahn had announced the advance the day before in the WDR. Several federal states such as Berlin have already lifted the prioritization for the vaccine. In Berlin you can get appointments for this from general practitioners.
BENEFITS AND RISKS OF ASTRAZENECA:
The British-Swedish manufacturer has been in the headlines again and again – although experts consider its vaccine Vaxzevria to be just as suitable as the vaccines of other manufacturers. When used in younger age groups, partially fatal blood clots in the brain rarely occurred 4 to 16 days after vaccination. That is why the Standing Vaccination Commission (Stiko) recommends its use for people aged 60 and over. In the age group, the risk-benefit balance is “clearly in favor of the vaccination”. Because with age, the risk of serious and fatal problems increases. However, vaccination with the preparation is also possible for younger people – “after medical advice and if the patient accepts the individual risk,” according to the vaccination commission.
According to the Robert Koch Institute, around 6.3 million Astrazeneca doses have now been vaccinated. According to the Federal Ministry of Health, 9.3 million Astrazeneca cans have been delivered to countries and wholesalers.
The Vaccination Commission advocates continuing to give preference to particularly vulnerable groups when it comes to vaccinations. With a persistently high willingness to vaccinate, there is a “still considerable proportion of people who are ready to vaccinate at high risk of a severe course of Covid 19 who have not yet had the opportunity to vaccinate.” This affects many 70 to 79-year-olds and even more 60 to 69-year-olds – a total of millions of people. Even with younger people with previous illnesses, only about a quarter were vaccinated once. If vaccines become increasingly available, priority levels could be adjusted regionally over the next few months. At the request of the German Press Agency, Stiko chairman Thomas Mertens stated that this declaration refers to the current Stiko recommendation – “also to Astrazeneca”. According to Spahn, the prioritization is expected to be abandoned in Germany in June.
FLEXIBILITY AT ASTRAZENECA:
In future, according to the Spahn’s draft, the doctor, in consultation with the person being vaccinated, should be free to set the interval between four and twelve weeks for a second Astrazeneca vaccination. “Many people prefer to have the second vaccination earlier, also with a view to the summer – with Astrazenca that is also possible within the approval period,” said Spahn in the WDR. Astrazeneca-vaccinated people would then have to wait less long until the corona restrictions were removed. Relief for vaccinated people has now passed the Bundestag and is to be sealed in the Bundesrat this Friday. However, Astrazenca-vaccinated people would have the disadvantage of possibly less efficacy in the case of an earlier second injection.
The Vaccination Commission recommends an interval of 12 weeks between the first and second dose for the preparation. The background to this are observations that the longer distance leads to better effectiveness. According to a report by the European approval authority EMA, the effectiveness of a two-time vaccination with an interval of four to eight weeks is 50.4 percent. At 12 and more weeks it increases to 72.1 percent to 82.4 percent.
VACCINATIONS FOR 12 TO 16 YEARS OLD:
In Canada, the vaccine from Biontech / Pfizer, which was initially only released from the age of 16, can be administered to 12 to 15 year-olds. In the USA, approval from the age of 12 could take place in the next few days. The European approval authority EMA wants to give its vote in June. A clinical study in the US age group 12 to 15 showed 100 percent effectiveness. According to the federal government’s draft resolution for the round with the federal states, the aim is to offer all 12 to 18-year-olds a vaccination offer with Biontech by the end of the summer vacation. Around ten million doses are required for the first and second vaccination of these vintages. The federal states should develop appropriate concepts – for example with explicit invitations to the vaccination centers or series vaccinations in the schools./bw/ggr/sam/tr/ctt/DP/he